Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 9Neoplasms 8Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neuroendocrine Tumors 1

Interventions

Cisplatin 101Radiotherapy 53Brachytherapy 41Paclitaxel 37Carboplatin 36Surveys and Questionnaires 28Blood Specimen Collection 20pembrolizumab 19Radiation 17Magnetic Resonance Spectroscopy 17Drug Therapy 17Colposcopy 16Methods 14Bevacizumab 14Early Intervention, Educational 12toripalimab 11Topotecan 11Radiotherapy, Intensity-Modulated 11Papanicolaou Test 11Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Chemoradiotherapy 11Biopsy 11camrelizumab 10Mass Screening 10Gemcitabine 10Patient Navigation 9Papillomavirus Vaccines 9Nivolumab 9Fluorodeoxyglucose F18 9Educational Status 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uterine Cervical Neoplasms × talazoparib × Clear all
NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡